论文信息 - Osimertinib combined with durvalumab in EGFR‐mutant non‐small cell lung cancer: Results from the TATTON phase Ib trial: 136O - 字舞流文

Osimertinib combined with durvalumab in EGFR‐mutant non‐small cell lung cancer: Results from the TATTON phase Ib trial: 136O

M. Ahn | H. Saka | S. Ramalingam | G. Oxnard | S. Kim | A. Walding | M. Cantarini | K. Goto | J. Yang | H. Yu | J. Yang | Xiangning Huang | Liu Yang | L. Yang | H. Yu | H. Yu | H. Yu